MX2023008598A - Agentes de interleuquina-2 y usos de los mismos. - Google Patents
Agentes de interleuquina-2 y usos de los mismos.Info
- Publication number
- MX2023008598A MX2023008598A MX2023008598A MX2023008598A MX2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A
- Authority
- MX
- Mexico
- Prior art keywords
- mutants
- interleukin
- agents
- variants
- treat
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 4
- 102000000588 Interleukin-2 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se divulgan agentes de IL-2 que comprenden variantes de IL-2, así como métodos, composiciones y usos de los mismos. Los agentes de IL-2 descritos en el presente documento pueden utilizarse para tratar y/o prevenir diversos trastornos y afecciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163139736P | 2021-01-20 | 2021-01-20 | |
US202163281397P | 2021-11-19 | 2021-11-19 | |
PCT/US2022/013141 WO2022159590A1 (en) | 2021-01-20 | 2022-01-20 | Interleukin-2 mutants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023008598A true MX2023008598A (es) | 2023-08-10 |
Family
ID=80446172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023008598A MX2023008598A (es) | 2021-01-20 | 2022-01-20 | Agentes de interleuquina-2 y usos de los mismos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220226442A1 (es) |
EP (1) | EP4281101A1 (es) |
JP (1) | JP2024503506A (es) |
KR (1) | KR20230147072A (es) |
AU (1) | AU2022211021A1 (es) |
CA (1) | CA3208934A1 (es) |
MX (1) | MX2023008598A (es) |
TW (1) | TW202245825A (es) |
WO (1) | WO2022159590A1 (es) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
WO2016164937A2 (en) | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
JP7464389B2 (ja) | 2016-08-02 | 2024-04-09 | ビステラ, インコーポレイテッド | 操作されたポリペプチドおよびその使用 |
US10174092B1 (en) * | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
CN114450298A (zh) | 2019-07-26 | 2022-05-06 | 威特拉公司 | 白介素-2制剂及其用途 |
-
2022
- 2022-01-20 TW TW111102358A patent/TW202245825A/zh unknown
- 2022-01-20 MX MX2023008598A patent/MX2023008598A/es unknown
- 2022-01-20 CA CA3208934A patent/CA3208934A1/en active Pending
- 2022-01-20 KR KR1020237027881A patent/KR20230147072A/ko unknown
- 2022-01-20 AU AU2022211021A patent/AU2022211021A1/en active Pending
- 2022-01-20 US US17/580,038 patent/US20220226442A1/en not_active Abandoned
- 2022-01-20 WO PCT/US2022/013141 patent/WO2022159590A1/en active Application Filing
- 2022-01-20 JP JP2023543358A patent/JP2024503506A/ja active Pending
- 2022-01-20 EP EP22705612.4A patent/EP4281101A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3208934A1 (en) | 2022-07-28 |
US20220226442A1 (en) | 2022-07-21 |
WO2022159590A1 (en) | 2022-07-28 |
EP4281101A1 (en) | 2023-11-29 |
TW202245825A (zh) | 2022-12-01 |
AU2022211021A1 (en) | 2023-08-03 |
JP2024503506A (ja) | 2024-01-25 |
KR20230147072A (ko) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MX2022009164A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. | |
MX2021002180A (es) | Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. | |
PH12020551140A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12020551144A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
MX2022012474A (es) | Compuestos y usos de estos. | |
ZA202207804B (en) | Compounds and uses thereof | |
MX2020006355A (es) | Pirrolidinamidas ii sustituidas. | |
WO2018178243A3 (en) | Dihydrotetrabenazine for use in the treatment a movement disorder | |
NZ756936A (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
MX2022009308A (es) | Compuestos y usos de estos. | |
MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
PH12020551071A1 (en) | Compositions and methods for treating retinal disorders | |
CR20220656A (es) | Unión de anticuerpos multiespecíficos a bcma | |
MX2022009367A (es) | Compuestos y usos de estos. | |
ZA202209970B (en) | Neurotoxin compositions for use in treating cardiovascular disorders | |
CR20230474A (es) | Anticuerpos anti-cd19 y estructuras car-t |